Radisys Introduces White Box Combo PON Optical Line Terminals for Next-Gen FTTX Networks
13.7.2021 15:00:00 EEST | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, today introduced the Radisys Combo PON Optical Line Terminal (OLT) as part of the Radisys Connect Open Broadband portfolio for broadband service providers. The complete family of Radisys OLTs includes 16 and 32-port versions—a variant of which is the Radisys white box Combo PON OLT that supports both G-PON (2.488 Gbps downstream / 1.244 Gbps upstream) and XGS-PON (10 Gbps symmetrical) within the same PON port of the OLT. The white box OLTs are based on the VOLTHA/SEBA reference architecture and are field-hardened and scaled for commercial deployments today.
News Highlights
- A growing number of global service providers are moving forward with XGS-PON as their next-generation PON technology of choice. Analyst firm Dell-Oro Group predicts XGS-PON will be the favored PON technology for the future.
- Radisys’ Combo PON OLT allows broadband providers to take advantage of pervasive G-PON technology while giving them a flexible upgrade path to scale up and rollout XGS-PON deployments without costly rip and replace.
-
Radisys’ Combo PON OLT is an open, flexible, highly scalable telco-grade white box designed to address service providers’ key needs.
- Full PON port flexibility enables G-PON, XGS-PON or Combo PON (G-PON and XGS-PON) on any port on the same platform.
- Open architecture delivers datacenter-driven cost efficiencies and high port densities, making it suitable for residential, cloud and enterprise services to simplify deployments and reduce operating expenses.
- Compatibility with any ONF VOLTHA-based software, including Radisys’ Connect Broadband Access Controller (CBAC) software, allows service providers to scale hardware up or down while the management software and all other Connect Open Broadband components remain intact.
- Flexibility to deploy virtualized functions either in a distributed fashion running within the OLT CPU, or as a centralized function hosted on an external server or a public or private cloud.
- Radisys’ Combo PON OLTs are part of the Connect Open Broadband product suite, which includes open and disaggregated software, hardware and management.
- The complete family of Radisys OLTs also includes the 16 and 32-port OLTs. The Radisys 32 port G-PON OLT (RLT-3200G) was recently certified for VOLTHA v2.8 through Open Networking Foundation’s Continuous Certification Program.
“Radisys’ Combo PON OLTs give broadband providers an optimal economic advantage with the flexibility to use both G-PON and XGS-PON in their networks and through a reduction in space and power consumption,” said Harris Razak, senior vice president of Broadband Access, Radisys. “All products in the Connect Open Broadband portfolio utilize the same management system and controlling software, allowing our provider customers to choose the features and capacity they want while keeping other network elements the same, lowering their total cost of ownership and optimizing their Capex and Opex.”
“We are pleased that Radisys’ 32-port G-PON OLT has been named a certified VOLTHA product within the ONF Continuous Certification Program. This certification, along with the introduction of the Radisys Combo PON OLT with support for VOLTHA/SEBA, offers broadband service providers with greater solution choices for their FTTX deployments,” said Guru Parulkar, ONF Executive Director. “As an ONF Partner Member, Radisys has been instrumental in the development of ONF open reference designs as well as the commercialization of ONF-based solutions. The Continuous Certification Program ensures that service providers can easily identify certified products for specific ONF projects within a vibrant ecosystem of vendors delivering and deploying ONF open source platforms.”
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.Radisys.com.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005445/en/
Contact information
Nereus for Radisys
Lori Mesecke, +1-503-459-9150
lmesecke@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom